Amberly Eversole, PA
Medical · Springfield, MONPI 1508620733
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,328 of the $4,468 with a category attached, or 74.5%. 26 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 35.9% of the total.
Across 136 payments — averaging $32.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$2K
- Amgen$507
- Novo Nordisk$322
- Dexcom, Inc.$301
- Abbott$220
- Recordati_rare_diseases_inc.$209
- plus $1K from 20 others
What the payments were for
- Travel & lodging$1,14026%
- Food & beverage$3,32874%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 3 | $1,604 |
| Amgen | 15 | $507 |
| Novo Nordisk | 18 | $322 |
| Dexcom, Inc. | 32 | $301 |
| Abbott | 7 | $220 |
| Recordati_rare_diseases_inc. | 6 | $209 |
| Bayer | 5 | $176 |
| Sanofi-aventis U.S. LLC | 5 | $172 |
| Lilly USA, LLC | 9 | $154 |
| Radius Health, Inc. | 6 | $154 |
| Insulet Corporation | 4 | $95 |
| Antares Pharma, Inc. | 5 | $88 |
| Medtronic | 1 | $75 |
| Chiesi USA, Inc. | 4 | $73 |
| Averitas Pharma Inc. | 2 | $40 |
| Novartis | 2 | $37 |
| Pfizer | 2 | $35 |
| Boehringer Ingelheim | 2 | $33 |
| Neurocrine Biosciences, Inc. | 1 | $28 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $24 |
| Alvogen Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $21 |
| AbbVie | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$1,604
- Repatha$151
- Kerendia$125
- TZIELD$124
- TEPEZZA$123
How this compares
$4,468 in reported general payments places this provider in the 85th percentile of 198 medical providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 34 | $40,852 |
| OzempicSemaglutide | 39 | $36,597 |
| FarxigaDapagliflozin Propanediol | 39 | $34,233 |
| TrulicityDulaglutide | 23 | $26,683 |
| JardianceEmpagliflozin | 17 | $13,489 |
| Novolog FlexpenInsulin Aspart | 24 | $9,667 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $5,458 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $5,286 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 14 | $5,141 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $3,102 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $2,242 |
| Rosuvastatin Calcium | 16 | $515 |
| Liothyronine Sodium | 16 | $489 |
| Atorvastatin Calcium | 32 | $448 |
| Levothyroxine Sodium | 65 | $445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $154 | $67,53557 claims |
| Novo NordiskOzempic | $322 | $36,59739 claims |
| Boehringer IngelheimJardiance | $33 | $13,48917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 medical providers in Missouri.
Other medical in Springfield
- Melanie ChisamSpringfield$92K
- Dustin BartlettSpringfield$21K
- Alina CumminsSpringfield$6K
- Kara WalkerSpringfield$4K
- Amber BeckSpringfield$2K
- Kaitlin FosterSpringfield$2K
- Jessica SpencerSpringfield$1K
- Emily JensenBowling Green$51K
- Sarah WilmsmeyerChesterfield$22K
- Amy MosmanSaint Louis$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.